# Biomarker Assessment of Glutamatergic Target Engagement

> **NCT02134951** · PHASE4 · COMPLETED · sponsor: **New York State Psychiatric Institute** · enrollment: 65 (actual)

## Conditions studied

- Healthy Controls

## Interventions

- **DRUG:** Ketamine
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT02134951
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2015-10
- **Final completion:** 2015-11
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2018-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02134951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02134951, "Biomarker Assessment of Glutamatergic Target Engagement". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02134951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*